Phenome-wide association study for CYP2A6 alleles: rs113288603 is associated with hearing loss symptoms in elderly smokers

[1]  Hongyu Zhao,et al.  A genome-wide gene-by-trauma interaction study of alcohol misuse in two independent cohorts identifies PRKG1 as a risk locus , 2017, Molecular Psychiatry.

[2]  Elliot A. Stein,et al.  CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers , 2017, Biological Psychiatry.

[3]  Hongyu Zhao,et al.  Genome‐wide association study of body mass index in subjects with alcohol dependence , 2017, Addiction biology.

[4]  R. Kessler,et al.  Cross-Phenotype Polygenic Risk Score Analysis of Persistent Post-Concussive Symptoms in U.S. Army Soldiers with Deployment-Acquired Traumatic Brain Injury. , 2017, Journal of neurotrauma.

[5]  Hongyu Zhao,et al.  The Interplay Between Risky Sexual Behaviors and Alcohol Dependence: Genome-Wide Association and Neuroimaging Support for LHPP as a Risk Gene , 2017, Neuropsychopharmacology.

[6]  C. Amos,et al.  Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. , 2016, Cancer research.

[7]  R. Polimanti,et al.  Allergy-specific Phenome-Wide Association Study for Immunogenes in Turkish Children , 2016, Scientific Reports.

[8]  N. Benowitz,et al.  Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. , 2016, Trends in cardiovascular medicine.

[9]  Angela R Laird,et al.  Chronic cigarette smoking is linked with structural alterations in brain regions showing acute nicotinic drug-induced functional modulations , 2016, Behavioral and Brain Functions.

[10]  Louise Hickson,et al.  Auditory deprivation and health in the elderly. , 2016, Maturitas.

[11]  Joel Gelernter,et al.  Phenome-Wide Association Study for Alcohol and Nicotine Risk Alleles in 26394 Women , 2016, Neuropsychopharmacology.

[12]  H. Javitz,et al.  Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries , 2016, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[13]  Dana C. Crawford,et al.  Unravelling the human genome–phenome relationship using phenome-wide association studies , 2016, Nature Reviews Genetics.

[14]  Gerard Tromp,et al.  The phenotypic legacy of admixture between modern humans and Neandertals , 2016, Science.

[15]  F. Speizer,et al.  Smoking and Mortality - Beyond Established Causes. , 2016, The New England journal of medicine.

[16]  H. Yi,et al.  Recent Advances in Cerebellar Ischemic Stroke Syndromes Causing Vertigo and Hearing Loss , 2016, The Cerebellum.

[17]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[18]  T. Lehtimäki,et al.  A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism , 2015, PLoS genetics.

[19]  M. Schwab,et al.  Enduring and emerging challenges of informed consent. , 2015, The New England journal of medicine.

[20]  L. Kiemeney,et al.  CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. , 2015, Journal of the National Cancer Institute.

[21]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[22]  J. Syka,et al.  Age-related changes in the central auditory system , 2015, Cell and Tissue Research.

[23]  S. Grando,et al.  Connections of nicotine to cancer , 2014, Nature Reviews Cancer.

[24]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[25]  R. Altman,et al.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8 , 2012, Pharmacogenetics and genomics.

[26]  R. Altman,et al.  PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6 , 2012, Pharmacogenetics and genomics.

[27]  O. Delaneau,et al.  A linear complexity phasing method for thousands of genomes , 2011, Nature Methods.

[28]  Andrey A. Shabalin,et al.  Matrix eQTL: ultra fast eQTL analysis via large matrix operations , 2011, Bioinform..

[29]  J. Bower,et al.  Increased activation of the human cerebellum during pitch discrimination: A positron emission tomography (PET) study , 2011, Hearing Research.

[30]  J. Marchini,et al.  Genotype Imputation with Thousands of Genomes , 2011, G3: Genes | Genomes | Genetics.

[31]  K. Kellar,et al.  Cerebellar Nicotinic Cholinergic Receptors are Intrinsic to the Cerebellum: Implications for Diverse Functional Roles , 2011, The Cerebellum.

[32]  Ming D. Li,et al.  Genome-wide meta-analyses identify multiple loci associated with smoking behavior , 2010, Nature Genetics.

[33]  Ming-Huei Chen,et al.  GWAF: an R package for genome-wide association analyses with family data , 2010, Bioinform..

[34]  Paola Sebastiani,et al.  A family longevity selection score: ranking sibships by their longevity, size, and availability for study. , 2009, American journal of epidemiology.

[35]  Jeremy D. Schmahmann,et al.  Pitch discrimination in cerebellar patients: Evidence for a sensory deficit , 2009, Brain Research.

[36]  P. Dasgupta,et al.  Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases. , 2009, Pharmacology & therapeutics.

[37]  E. Platz,et al.  Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999-2004. , 2008, Archives of internal medicine.

[38]  Nicholas G Martin,et al.  Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. , 2007, Human molecular genetics.

[39]  J. Mackay,et al.  The Tobacco Atlas , 2002 .

[40]  R. Klein,et al.  Cigarette smoking and hearing loss: the epidemiology of hearing loss study. , 1998, JAMA.

[41]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.